Inventiva Reaffirms Runway and NATiV3 Timeline in Q4 Earnings Call

What happened

Inventiva held its Q4 2025 earnings call on March 31, 2026, following the release of audited FY2025 results, which management confirmed extend cash runway to mid-Q1 2027 with €230.9 million in combined cash and short-term deposits. They reiterated that the NATiV3 Phase 3 trial for lanifibranor remains on track for a topline readout in 2H 2026, with no new safety signals or protocol changes reported. Operating cash burn for FY2025 was €104.6 million, up 22% year-over-year, underscoring persistent financial strain despite recent equity raises. The call highlighted ongoing reliance on external financing and milestone payments, as the company lacks product revenue and faces negative equity. Management's updates focused on maintaining trial integrity, particularly the <30% discontinuation rate before Week 72, but offered no major surprises beyond previously disclosed guidance.

Implication

The confirmed cash runway to mid-Q1 2027 mitigates near-term dilution fears, but sustained high burn rates necessitate vigilance for potential pre-readout financing needs. Stable NATiV3 trial progress is a positive signal, yet any slippage in discontinuation rates or safety could swiftly undermine investor confidence and trigger downside. Increasing competition from approved MASH therapies like Rezdiffra and Wegovy raises the efficacy bar for lanifibranor, adding pressure to the 2H 2026 readout. Without revenue streams, the stock's valuation remains purely speculative, tied to clinical outcomes and prone to volatility around key milestones. A WAIT rating is still justified, as investors should await clearer data from upcoming quarterly updates and trial integrity checks before considering entry.

Thesis delta

The Q4 earnings call did not shift the investment thesis, as management's updates aligned with the base scenario of runway preservation and trial continuity outlined in the DeepValue report. However, it reinforced the critical need for monitoring cash burn and NATiV3 integrity, with no material new information to change the risk-reward balance. Investors should continue to wait for the March 30 audited results and further trial updates before reassessing the entry point.